Newron Sweden AB
Newron Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Their lead compound, evenamide, is a first-in-class glutamate modulator in Phase III development, aiming to become the first add-on therapy for treatment-resistant schizophrenia. The company has a proven track record in CNS therapies, with their Parkinson’s treatment Xadago® (safinamide) approved in over 20 markets. They are committed to improving patients' quality of life through innovative treatments and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
Newron Sweden AB
via Antonio Meucci 3, 20091 Bresso (Mi) Italy
Patents
Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives
US-12291495-B2
View DetailsProcess for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives
US-12134589-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9856207-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9603832-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9585869-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9505708-B2
View Details
Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives
US-12291495-B2
View DetailsProcess for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives
US-12134589-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9856207-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9603832-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9585869-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9505708-B2
View DetailsProducts
Investigational oral glutamate-modulating small molecule (lead candidate)
Oral small-molecule modulator of glutamate neurotransmission via selective voltage-gated sodium channel inhibition, developed as an add-on therapy for treatment-resistant and chronic schizophrenia; currently in late-stage clinical development.
Commercialized Parkinson's disease small-molecule therapy (historical asset)
Commercially approved small-molecule therapy for Parkinson's disease that the company previously developed and licensed for global commercialization by partners.
Investigational oral glutamate-modulating small molecule (lead candidate)
Oral small-molecule modulator of glutamate neurotransmission via selective voltage-gated sodium channel inhibition, developed as an add-on therapy for treatment-resistant and chronic schizophrenia; currently in late-stage clinical development.
Commercialized Parkinson's disease small-molecule therapy (historical asset)
Commercially approved small-molecule therapy for Parkinson's disease that the company previously developed and licensed for global commercialization by partners.
Services
Negotiation and management of territorial licensing and co-development agreements for CNS compounds; support for commercialization partnerships.
Co-development and collaboration with external CROs, KOLs and investigators to design and run CNS clinical trials and present data at scientific meetings.
Negotiation and management of territorial licensing and co-development agreements for CNS compounds; support for commercialization partnerships.
Co-development and collaboration with external CROs, KOLs and investigators to design and run CNS clinical trials and present data at scientific meetings.
Expertise Areas
- Clinical trial management
- CNS drug development
- Schizophrenia therapeutic development
- Global clinical operations
Key Technologies
- Small-molecule drug development
- Voltage-gated sodium channel modulation
- Glutamate-modulating mechanism of action
- Preclinical animal models of psychosis